{"id":"https://openalex.org/W2903677519","doi":"https://doi.org/10.1007/s40262-018-0728-4","title":"Safety and Pharmacokinetics of Single and Multiple Ascending Doses of the Novel Oral Human GLP-1 Analogue, Oral Semaglutide, in Healthy Subjects and Subjects with Type 2 Diabetes","display_name":"Safety and Pharmacokinetics of Single and Multiple Ascending Doses of the Novel Oral Human GLP-1 Analogue, Oral Semaglutide, in Healthy Subjects and Subjects with Type 2 Diabetes","alternate_titles":[],"publication_year":2018,"publication_date":"2018-12-18","ids":{"openalex":"https://openalex.org/W2903677519","doi":"https://doi.org/10.1007/s40262-018-0728-4","mag":"2903677519","pmid":"https://pubmed.ncbi.nlm.nih.gov/30565096"},"language":"en","primary_location":{"id":"doi:10.1007/s40262-018-0728-4","doi":"https://doi.org/10.1007/s40262-018-0728-4","is_oa":true,"landing_page_url":"https://doi.org/10.1007/s40262-018-0728-4","pdf_url":"https://link.springer.com/content/pdf/10.1007/s40262-018-0728-4.pdf","source":{"id":"https://openalex.org/S69290020","display_name":"Clinical Pharmacokinetics","issn_l":"0312-5963","issn":["0312-5963","1179-1926"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core","dongbi-b","doyens","jufo-2","ki-jl-2","medline","norway-2","poland-140","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320330","host_organization_name":"Adis, Springer Healthcare","host_organization_lineage":["https://openalex.org/P4310320330","https://openalex.org/P4310319965"],"host_organization_lineage_names":["Adis, Springer Healthcare","Springer Nature"],"type":"journal"},"license":"cc-by-nc","license_id":"https://openalex.org/licenses/cc-by-nc","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Clinical Pharmacokinetics","raw_type":"journal-article"},"parent_works":[],"lineage":["https://openalex.org/W2903677519"],"child_works_count":0,"type":"article","is_traditional":true,"indexed_in":["crossref","pubmed"],"open_access":{"is_oa":true,"oa_status":"hybrid","oa_url":"https://link.springer.com/content/pdf/10.1007/s40262-018-0728-4.pdf","any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5048052863","display_name":"Charlotte Granhall","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I189090001","display_name":"Novo Nordisk (Denmark)","ror":"https://ror.org/0435rc536","country_code":"DK","type":"company","lineage":["https://openalex.org/I189090001","https://openalex.org/I2801134892","https://openalex.org/I4210159963"]}],"countries":["DK"],"is_corresponding":false,"raw_author_name":"Charlotte Granhall","raw_affiliation_strings":["Novo Nordisk A/S, Vandt\u00e5rnsvej 114, 2860, S\u00f8borg, Denmark"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Novo Nordisk A/S, Vandt\u00e5rnsvej 114, 2860, S\u00f8borg, Denmark","institution_ids":["https://openalex.org/I189090001"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5026337749","display_name":"Morten Donsmark","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I189090001","display_name":"Novo Nordisk (Denmark)","ror":"https://ror.org/0435rc536","country_code":"DK","type":"company","lineage":["https://openalex.org/I189090001","https://openalex.org/I2801134892","https://openalex.org/I4210159963"]}],"countries":["DK"],"is_corresponding":false,"raw_author_name":"Morten Donsmark","raw_affiliation_strings":["Novo Nordisk A/S, Vandt\u00e5rnsvej 114, 2860, S\u00f8borg, Denmark"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Novo Nordisk A/S, Vandt\u00e5rnsvej 114, 2860, S\u00f8borg, Denmark","institution_ids":["https://openalex.org/I189090001"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5027926667","display_name":"Thalia Marie Blicher","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I189090001","display_name":"Novo Nordisk (Denmark)","ror":"https://ror.org/0435rc536","country_code":"DK","type":"company","lineage":["https://openalex.org/I189090001","https://openalex.org/I2801134892","https://openalex.org/I4210159963"]}],"countries":["DK"],"is_corresponding":false,"raw_author_name":"Thalia M. Blicher","raw_affiliation_strings":["Novo Nordisk A/S, Vandt\u00e5rnsvej 114, 2860, S\u00f8borg, Denmark"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Novo Nordisk A/S, Vandt\u00e5rnsvej 114, 2860, S\u00f8borg, Denmark","institution_ids":["https://openalex.org/I189090001"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5020342489","display_name":"Georg Golor","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Georg Golor","raw_affiliation_strings":["Early Phase Clinical Unit-Berlin, Parexel International GmbH, Klinikum Westend-Haus 18, Spandauer Damm 130, 14050, Berlin, Germany"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Early Phase Clinical Unit-Berlin, Parexel International GmbH, Klinikum Westend-Haus 18, Spandauer Damm 130, 14050, Berlin, Germany","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5023510885","display_name":"Flemming L. S\u00f8ndergaard","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I189090001","display_name":"Novo Nordisk (Denmark)","ror":"https://ror.org/0435rc536","country_code":"DK","type":"company","lineage":["https://openalex.org/I189090001","https://openalex.org/I2801134892","https://openalex.org/I4210159963"]}],"countries":["DK"],"is_corresponding":false,"raw_author_name":"Flemming L. S\u00f8ndergaard","raw_affiliation_strings":["Novo Nordisk A/S, Alfred Nobels Vej 27, 9220, Aalborg \u00d8, Denmark"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Novo Nordisk A/S, Alfred Nobels Vej 27, 9220, Aalborg \u00d8, Denmark","institution_ids":["https://openalex.org/I189090001"]}]},{"author_position":"middle","author":{"id":null,"display_name":"Mette Thomsen","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I189090001","display_name":"Novo Nordisk (Denmark)","ror":"https://ror.org/0435rc536","country_code":"DK","type":"company","lineage":["https://openalex.org/I189090001","https://openalex.org/I2801134892","https://openalex.org/I4210159963"]}],"countries":["DK"],"is_corresponding":false,"raw_author_name":"Mette Thomsen","raw_affiliation_strings":["Novo Nordisk A/S, Vandt\u00e5rnsvej 114, 2860, S\u00f8borg, Denmark"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Novo Nordisk A/S, Vandt\u00e5rnsvej 114, 2860, S\u00f8borg, Denmark","institution_ids":["https://openalex.org/I189090001"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5043297080","display_name":"Tine A. B\u00e6kdal","orcid":"https://orcid.org/0000-0002-1348-0352","observed_orcids":["https://orcid.org/0000-0002-1348-0352"]},"institutions":[{"id":"https://openalex.org/I189090001","display_name":"Novo Nordisk (Denmark)","ror":"https://ror.org/0435rc536","country_code":"DK","type":"company","lineage":["https://openalex.org/I189090001","https://openalex.org/I2801134892","https://openalex.org/I4210159963"]}],"countries":["DK"],"is_corresponding":true,"raw_author_name":"Tine A. B\u00e6kdal","raw_affiliation_strings":["Novo Nordisk A/S, Vandt\u00e5rnsvej 114, 2860, S\u00f8borg, Denmark. tabq@novonordisk.com","Novo Nordisk A/S, Vandt\u00e5rnsvej 114, 2860, S\u00f8borg, Denmark"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Novo Nordisk A/S, Vandt\u00e5rnsvej 114, 2860, S\u00f8borg, Denmark. tabq@novonordisk.com","institution_ids":["https://openalex.org/I189090001"]},{"raw_affiliation_string":"Novo Nordisk A/S, Vandt\u00e5rnsvej 114, 2860, S\u00f8borg, Denmark","institution_ids":["https://openalex.org/I189090001"]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":1,"corresponding_author_ids":["https://openalex.org/A5043297080"],"corresponding_institution_ids":["https://openalex.org/I189090001"],"apc_list":{"value":4990,"currency":"USD","value_usd":4990},"apc_paid":{"value":4990,"currency":"USD","value_usd":4990},"fwci":12.3969,"has_fulltext":true,"cited_by_count":213,"citation_normalized_percentile":{"value":0.99296208,"is_in_top_1_percent":true,"is_in_top_10_percent":true},"cited_by_percentile_year":{"min":99,"max":100},"biblio":{"volume":"58","issue":"6","first_page":"781","last_page":"791"},"is_retracted":false,"is_pulled":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10401","display_name":"Diabetes Treatment and Management","score":0.9965999722480774,"subfield":{"id":"https://openalex.org/subfields/2712","display_name":"Endocrinology, Diabetes and Metabolism"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10401","display_name":"Diabetes Treatment and Management","score":0.9965999722480774,"subfield":{"id":"https://openalex.org/subfields/2712","display_name":"Endocrinology, Diabetes and Metabolism"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10560","display_name":"Diabetes Management and Research","score":0.0010999999940395355,"subfield":{"id":"https://openalex.org/subfields/2712","display_name":"Endocrinology, Diabetes and Metabolism"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T12539","display_name":"Pharmacology and Obesity Treatment","score":0.0005000000237487257,"subfield":{"id":"https://openalex.org/subfields/2736","display_name":"Pharmacology (medical)"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/oral-semaglutide","display_name":"oral semaglutide","score":0.9990000128746033},{"id":"https://openalex.org/keywords/semaglutide","display_name":"semaglutide","score":0.847000002861023},{"id":"https://openalex.org/keywords/glp-1-receptor-agonists","display_name":"GLP-1 receptor agonists","score":0.8610000014305115},{"id":"https://openalex.org/keywords/snac","display_name":"SNAC","score":0.7889999747276306},{"id":"https://openalex.org/keywords/absorption-enhancers","display_name":"absorption enhancers","score":0.9279999732971191},{"id":"https://openalex.org/keywords/pharmacokinetics","display_name":"pharmacokinetics","score":0.8679999709129333},{"id":"https://openalex.org/keywords/safety","display_name":"safety","score":0.5400000214576721},{"id":"https://openalex.org/keywords/type-2-diabetes","display_name":"type 2 diabetes","score":0.9559999704360962},{"id":"https://openalex.org/keywords/dose-proportionality","display_name":"dose proportionality","score":0.9459999799728394},{"id":"https://openalex.org/keywords/half-life","display_name":"half-life","score":0.6830000281333923},{"id":"https://openalex.org/keywords/gastrointestinal-side-effects","display_name":"gastrointestinal adverse effects","score":0.6589999794960022}],"concepts":[{"id":"https://openalex.org/C2909862629","wikidata":"https://www.wikidata.org/wiki/Q27261089","display_name":"Semaglutide","level":5,"score":0.9390379190444946},{"id":"https://openalex.org/C112705442","wikidata":"https://www.wikidata.org/wiki/Q323936","display_name":"Pharmacokinetics","level":2,"score":0.7868325710296631},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.7682406306266785},{"id":"https://openalex.org/C2777180221","wikidata":"https://www.wikidata.org/wiki/Q3025883","display_name":"Type 2 diabetes","level":3,"score":0.5075870752334595},{"id":"https://openalex.org/C98274493","wikidata":"https://www.wikidata.org/wiki/Q128406","display_name":"Pharmacology","level":1,"score":0.3720528185367584},{"id":"https://openalex.org/C555293320","wikidata":"https://www.wikidata.org/wiki/Q12206","display_name":"Diabetes mellitus","level":2,"score":0.32830965518951416},{"id":"https://openalex.org/C134018914","wikidata":"https://www.wikidata.org/wiki/Q162606","display_name":"Endocrinology","level":1,"score":0.23650816082954407},{"id":"https://openalex.org/C2781308992","wikidata":"https://www.wikidata.org/wiki/Q2526479","display_name":"Liraglutide","level":4,"score":0.0}],"mesh":[{"descriptor_ui":"D000099194","descriptor_name":"Semaglutide","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000284","descriptor_name":"Administration, Oral","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000293","descriptor_name":"Adolescent","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000328","descriptor_name":"Adult","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D003924","descriptor_name":"Diabetes Mellitus, Type 2","qualifier_ui":"Q000097","qualifier_name":"blood","is_major_topic":false},{"descriptor_ui":"D003924","descriptor_name":"Diabetes Mellitus, Type 2","qualifier_ui":"Q000188","qualifier_name":"drug therapy","is_major_topic":true},{"descriptor_ui":"D004305","descriptor_name":"Dose-Response Relationship, Drug","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D004311","descriptor_name":"Double-Blind Method","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D004763","descriptor_name":"Glucagon-Like Peptides","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":true},{"descriptor_ui":"D004763","descriptor_name":"Glucagon-Like Peptides","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":true},{"descriptor_ui":"D004763","descriptor_name":"Glucagon-Like Peptides","qualifier_ui":"Q000097","qualifier_name":"blood","is_major_topic":true},{"descriptor_ui":"D006801","descriptor_name":"Humans","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D007004","descriptor_name":"Hypoglycemic Agents","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":true},{"descriptor_ui":"D007004","descriptor_name":"Hypoglycemic Agents","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":true},{"descriptor_ui":"D007004","descriptor_name":"Hypoglycemic Agents","qualifier_ui":"Q000097","qualifier_name":"blood","is_major_topic":true},{"descriptor_ui":"D008297","descriptor_name":"Male","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D008657","descriptor_name":"Metabolic Clearance Rate","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D008875","descriptor_name":"Middle Aged","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D019540","descriptor_name":"Area Under Curve","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D052216","descriptor_name":"Glucagon-Like Peptide 1","qualifier_ui":"Q000031","qualifier_name":"analogs & derivatives","is_major_topic":true},{"descriptor_ui":"D055815","descriptor_name":"Young Adult","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D064368","descriptor_name":"Healthy Volunteers","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false}],"locations_count":2,"locations":[{"id":"doi:10.1007/s40262-018-0728-4","doi":"https://doi.org/10.1007/s40262-018-0728-4","is_oa":true,"landing_page_url":"https://doi.org/10.1007/s40262-018-0728-4","pdf_url":"https://link.springer.com/content/pdf/10.1007/s40262-018-0728-4.pdf","source":{"id":"https://openalex.org/S69290020","display_name":"Clinical Pharmacokinetics","issn_l":"0312-5963","issn":["0312-5963","1179-1926"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core","dongbi-b","doyens","jufo-2","ki-jl-2","medline","norway-2","poland-140","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320330","host_organization_name":"Adis, Springer Healthcare","host_organization_lineage":["https://openalex.org/P4310320330","https://openalex.org/P4310319965"],"host_organization_lineage_names":["Adis, Springer Healthcare","Springer Nature"],"type":"journal"},"license":"cc-by-nc","license_id":"https://openalex.org/licenses/cc-by-nc","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Clinical Pharmacokinetics","raw_type":"journal-article"},{"id":"pmid:30565096","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/30565096","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Clinical pharmacokinetics","raw_type":"Journal Article"}],"best_oa_location":{"id":"doi:10.1007/s40262-018-0728-4","doi":"https://doi.org/10.1007/s40262-018-0728-4","is_oa":true,"landing_page_url":"https://doi.org/10.1007/s40262-018-0728-4","pdf_url":"https://link.springer.com/content/pdf/10.1007/s40262-018-0728-4.pdf","source":{"id":"https://openalex.org/S69290020","display_name":"Clinical Pharmacokinetics","issn_l":"0312-5963","issn":["0312-5963","1179-1926"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core","dongbi-b","doyens","jufo-2","ki-jl-2","medline","norway-2","poland-140","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320330","host_organization_name":"Adis, Springer Healthcare","host_organization_lineage":["https://openalex.org/P4310320330","https://openalex.org/P4310319965"],"host_organization_lineage_names":["Adis, Springer Healthcare","Springer Nature"],"type":"journal"},"license":"cc-by-nc","license_id":"https://openalex.org/licenses/cc-by-nc","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Clinical Pharmacokinetics","raw_type":"journal-article"},"sustainable_development_goals":[{"display_name":"Good health and well-being","score":1.0,"id":"https://metadata.un.org/sdg/3"}],"study_designs":[{"display_name":"Clinical Trial","id":"https://openalex.org/study-designs/clinical-trial"}],"awards":[],"funders":[{"id":"https://openalex.org/F4320322436","display_name":"Novo Nordisk","ror":"https://ror.org/0435rc536"}],"has_content":{"grobid_xml":true,"pdf":true},"content_urls":{"pdf":"https://content.openalex.org/works/W2903677519.pdf","grobid_xml":"https://content.openalex.org/works/W2903677519.grobid-xml"},"referenced_works_count":11,"referenced_works":["https://openalex.org/W47093099","https://openalex.org/W1967079645","https://openalex.org/W2055249600","https://openalex.org/W2108116968","https://openalex.org/W2109598625","https://openalex.org/W2190748907","https://openalex.org/W2599272075","https://openalex.org/W2738743019","https://openalex.org/W2766836053","https://openalex.org/W2807957707","https://openalex.org/W2901306081"],"related_works":["https://openalex.org/W4399130340","https://openalex.org/W3035613208","https://openalex.org/W2929744948","https://openalex.org/W3164680927","https://openalex.org/W2795981708","https://openalex.org/W3095483723","https://openalex.org/W4294191216","https://openalex.org/W3152050242","https://openalex.org/W2948113371","https://openalex.org/W2944042183"],"abstract_inverted_index":{"BACKGROUND:":[0],"Oral":[1,112,214],"semaglutide":[2,31,51,54,79,101,113,141,155,167,189,203,215,233],"is":[3,234],"a":[4,42,65],"novel":[5],"tablet":[6],"containing":[7],"the":[8,17,130,138,152,208],"human":[9],"glucagon-like":[10],"peptide-1":[11],"(GLP\u20111)":[12],"analogue":[13],"semaglutide,":[14],"co-formulated":[15,55,146,216],"with":[16,56,62,87,92,109,129,147,161,173,184,217],"absorption":[18],"enhancer":[19],"sodium":[20],"N-(8-[2-hydroxybenzoyl]":[21],"amino)":[22],"caprylate":[23],"(SNAC).":[24],"The":[25,121,186,198,227],"safety":[26,199],"and":[27,89,116,176,182],"pharmacokinetics":[28],"of":[29,123,188,201],"oral":[30,50,78,100,166,202,232],"were":[32,127],"investigated":[33],"in":[34,118,168,171,194],"two":[35],"randomised,":[36],"double-blind,":[37],"placebo-controlled":[38],"trials.":[39,120],"METHODS:":[40],"In":[41,64,137,151],"single-dose,":[43],"first-in-human":[44],"trial,":[45,69,140,154],"135":[46],"healthy":[47,71,169,180],"males":[48,72,91,181,183],"received":[49,73,97],"(2-20":[52],"mg":[53,58,77,82,99,104,149,165,219],"150-600":[57],"SNAC)":[59],"or":[60,75,85,107],"placebo":[61,86,108],"SNAC.":[63,110,150],"10-week,":[66],"once-daily,":[67],"multiple-dose":[68,153],"84":[70],"20":[74,164],"40":[76,98,162],"(with":[80,102],"300":[81,103,148,218],"SNAC),":[83,105],"placebo,":[84,106],"SNAC,":[88],"23":[90],"type":[93],"2":[94],"diabetes":[95],"(T2D)":[96],"RESULTS:":[111],"was":[114,143,157,177,190,204,221],"safe":[115],"well-tolerated":[117],"both":[119],"majority":[122],"adverse":[124],"events":[125],"(AEs)":[126],"mild,":[128],"most":[131],"common":[132],"AEs":[133],"being":[134],"gastrointestinal":[135],"disorders.":[136],"single-dose":[139],"exposure":[142,156],"highest":[144],"when":[145],"approximately":[158,191],"twofold":[159],"higher":[160],"versus":[163],"males,":[170],"accordance":[172],"dose":[174],"proportionality,":[175],"similar":[178],"between":[179],"T2D.":[185],"half-life":[187],"1":[192],"week":[193],"all":[195],"groups.":[196],"CONCLUSION:":[197],"profile":[200],"as":[205],"expected":[206],"for":[207,223,236],"GLP-1":[209],"receptor":[210],"agonist":[211],"drug":[212],"class.":[213],"SNAC":[220],"chosen":[222],"further":[224],"clinical":[225],"development.":[226],"pharmacokinetic":[228],"results":[229],"supported":[230],"that":[231],"suitable":[235],"once-daily":[237],"dosing.":[238],"CLINICALTRIALS.":[239],"GOV":[240],"IDENTIFIERS:":[241],"NCT01037582,":[242],"NCT01686945.":[243]},"cited_by_api_url":"https://api.openalex.org/works?filter=cites:W2903677519","counts_by_year":[{"year":2026,"cited_by_count":36},{"year":2025,"cited_by_count":36},{"year":2024,"cited_by_count":27},{"year":2023,"cited_by_count":19},{"year":2022,"cited_by_count":25},{"year":2021,"cited_by_count":26},{"year":2020,"cited_by_count":29},{"year":2019,"cited_by_count":15}],"updated_date":"2026-11-16T12:05:36.265796","created_date":"2018-12-22T00:00:00"}
